ABEO
Price
$7.53
Change
-$0.40 (-5.04%)
Updated
Apr 18, 6:59 PM EST
22 days until earnings call
ATAI
Price
$1.91
Change
-$0.07 (-3.54%)
Updated
Apr 18, 6:59 PM EST
25 days until earnings call
Ad is loading...

Analysis and predictions ABEO vs ATAI

Header iconABEO vs ATAI Comparison
Open Charts ABEO vs ATAIBanner chart's image
Abeona Therapeutics
Price$7.53
Change-$0.40 (-5.04%)
Volume$136.16K
CapitalizationN/A
ATAI Life Sciences
Price$1.91
Change-$0.07 (-3.54%)
Volume$636.67K
CapitalizationN/A
View a ticker or compare two or three
ABEO vs ATAI Comparison Chart

Loading...

ABEODaily Signal changed days agoGain/Loss if shorted
 
Show more...
ATAIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ABEO vs. ATAI commentary
Apr 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Hold and ATAI is a StrongSell.

COMPARISON
Comparison
Apr 19, 2024
Stock price -- (ABEO: $7.93 vs. ATAI: $1.98)
Brand notoriety: ABEO and ATAI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 199% vs. ATAI: 80%
Market capitalization -- ABEO: $216.52M vs. ATAI: $328.73M
ABEO [@Biotechnology] is valued at $216.52M. ATAI’s [@Biotechnology] market capitalization is $328.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $551.2B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 0 FA rating(s) are green whileATAI’s FA Score has 1 green FA rating(s).

  • ABEO’s FA Score: 0 green, 5 red.
  • ATAI’s FA Score: 1 green, 4 red.
According to our system of comparison, ATAI is a better buy in the long-term than ABEO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 2 TA indicator(s) are bullish while ATAI’s TA Score has 4 bullish TA indicator(s).

  • ABEO’s TA Score: 2 bullish, 2 bearish.
  • ATAI’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ABEO is a better buy in the short-term than ATAI.

Price Growth

ABEO (@Biotechnology) experienced а +7.74% price change this week, while ATAI (@Biotechnology) price change was -18.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.57%. For the same industry, the average monthly price growth was -2.16%, and the average quarterly price growth was +1228.07%.

Reported Earning Dates

ABEO is expected to report earnings on Aug 08, 2024.

ATAI is expected to report earnings on Aug 12, 2024.

Industries' Descriptions

@Biotechnology (-7.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ABEO with price predictions.
OPEN
A.I.dvisor published
a Summary for ATAI with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ATAI($329M) has a higher market cap than ABEO($217M). ABEO YTD gains are higher at: 58.283 vs. ATAI (40.426).
ABEOATAIABEO / ATAI
Capitalization217M329M66%
EBITDAN/AN/A-
Gain YTD58.28340.426144%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
ABEO vs ATAI: Fundamental Ratings
ABEO
ATAI
OUTLOOK RATING
1..100
7014
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
10092
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
3739
P/E GROWTH RATING
1..100
10019
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABEO's Valuation (74) in the Pharmaceuticals Generic industry is in the same range as ATAI (84) in the Miscellaneous Commercial Services industry. This means that ABEO’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Profit vs Risk Rating (92) in the Miscellaneous Commercial Services industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that ATAI’s stock grew similarly to ABEO’s over the last 12 months.

ATAI's SMR Rating (94) in the Miscellaneous Commercial Services industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that ATAI’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's Price Growth Rating (37) in the Pharmaceuticals Generic industry is in the same range as ATAI (39) in the Miscellaneous Commercial Services industry. This means that ABEO’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's P/E Growth Rating (19) in the Miscellaneous Commercial Services industry is significantly better than the same rating for ABEO (100) in the Pharmaceuticals Generic industry. This means that ATAI’s stock grew significantly faster than ABEO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOATAI
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 22 days ago
74%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
ABEODaily Signal changed days agoGain/Loss if shorted
 
Show more...
ATAIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYUTX42.670.77
+1.84%
Rydex Utilities A
HFQCX5.880.03
+0.51%
Janus Henderson Global Equity Income C
BISRX16.620.02
+0.12%
Brandes International Small Cap EquityR6
ASLKX13.74-0.05
-0.36%
AB Select US Long/Short K
BRIFX13.28-0.11
-0.82%
Baron Real Estate Income Retail

ABEO and

Correlation & Price change

A.I.dvisor tells us that ABEO and AXON have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ABEO and AXON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+2.19%
AXON - ABEO
31%
Poorly correlated
-0.16%
ABUS - ABEO
30%
Poorly correlated
-4.79%
XNCR - ABEO
29%
Poorly correlated
+0.79%
AMRN - ABEO
28%
Poorly correlated
+2.37%
ARVN - ABEO
27%
Poorly correlated
+0.03%
More

ATAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATAI has been loosely correlated with ALLO. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ATAI jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATAI
1D Price
Change %
ATAI100%
-7.91%
ALLO - ATAI
48%
Loosely correlated
+0.29%
COUR - ATAI
45%
Loosely correlated
-1.25%
VCYT - ATAI
45%
Loosely correlated
-0.32%
MNMD - ATAI
45%
Loosely correlated
-3.54%
NTLA - ATAI
44%
Loosely correlated
-1.42%
More